409. Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network
Session: Poster Abstract Session: HIV - Antiretroviral Therapy
Friday, October 21, 2011
Room: Poster Hall B1

Background:  Outside of registrational trial data, there is limited information on the utilization and clinical outcomes of patients treated with etravirine-based (ETR) therapy, particularly on the use of ETR with protease inhibitors (PIs) other than darunavir (DRV) and with novel agents like raltegravir (RAL).  Methods: Demographic and clinical data were collected from adult patients in the HIV Research Network who were treatment-experienced and began an antiretroviral regimen in 2008 or 2009 that contained ETR; 6-month outcomes (durability, CD4 cell count change, and observed HIV RNA <400 copies/ml) are reported by regimen.   Results: Please see results in the below table.  

Conclusion:  Registrational studies for ETR all included DRV; 44% of the use in this cohort was in DRV-free regimens.  Although limited by lack of information on the baseline activity of ETR, outcomes appeared similar when ETR was used with DRV or other PIs; response rates were lower when ETR was not combined with a PI or RAL.      

 


Subject Category: H. HIV/AIDS and other retroviruses

Kelly Gebo, MD, MPH, John Hopkins University School of Medicine, Baltimore, MD, Cindy Voss, MA, Johns Hopkins University School of Medicine, Baltimore, MD and Joseph Mrus, MD, MSc, Tibotec Therapeutics, Titusville, NJ

Disclosures:

K. Gebo, Tibotec: Board Member and Grant Investigator, Grant recipient and Salary

C. Voss, None

J. Mrus, Tibotec Therapeutics: Employee, Salary

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.